Arrowhead Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $461.8M | $143.6M |
| FY2021 | — | $408.8M | $184.4M |
| FY2022 | — | $398.5M | $108.0M |
| FY2023 | — | $271.3M | $110.9M |
| FY2024 | — | $185.4M | $102.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $461.8M | $143.6M |
| FY2021 | — | $408.8M | $184.4M |
| FY2022 | — | $398.5M | $108.0M |
| FY2023 | — | $271.3M | $110.9M |
| FY2024 | — | $185.4M | $102.7M |